biomarkers; blood; cerebrospinal fluid; clinical report; consensus approach; harmonization; neurofilaments; Biomarkers; neurofilament protein L; Neurofilament Proteins; Humans; Biomarkers/cerebrospinal fluid; Biomarkers/blood; Surveys and Questionnaires; Practice Guidelines as Topic; Nervous System Diseases/diagnosis; Nervous System Diseases/cerebrospinal fluid; Neurofilament Proteins/cerebrospinal fluid; Neurofilament Proteins/blood; Nervous System Diseases; Epidemiology; Health Policy; Developmental Neuroscience; Neurology (clinical); Geriatrics and Gerontology; Cellular and Molecular Neuroscience; Psychiatry and Mental Health
Abstract :
[en] [en] INTRODUCTION: Neurofilament light chain (NfL) quantification aids in diagnosing and predicting neurological disorders, but clinical and laboratory practices vary across centers. Differences in result interpretation and reporting further challenge test commutability. This study aimed to review the global analytical and post-analytical methods used for NfL measurement in routine clinical practice across different contexts.
METHODS: We established an international working group (WG) and distributed a survey to its members to gather information on context of use (COU), (pre) analytical methods, cutoff usage, as well as the interpretation and reporting of NfL measurements.
RESULTS: Among the centers, 63% measured NfL in cerebrospinal fluid (CSF), 87% in blood, and 53% in both. COU was widespread, with 50% defining pathological cutoffs based on publications and 42% considering age. Reporting was primarily done through numeric results (95%).
DISCUSSION: Harmonizing cutoffs, reporting, and interpretation across various clinical contexts will facilitate the incorporation of this biomarker into routine clinical practice.
HIGHLIGHTS: Unique international overview of current analytical and post-analytical methods for neurofilament light chain (NfL) measurement in routine clinical practice. Tailored sheets for each neurological application. Strategies to harmonize cutoffs, reporting, and interpretation of NfL's measurement.
Disciplines :
Laboratory medicine & medical technology
Author, co-author :
Delaby, Constance ; Univ Montpellier, LBPC-PPC, CHU Montpellier, INSERM, Montpellier, France ; Department of Unitat de Memoria, Hospital de la Santa Creu iSant Pau - Biomedical Research Institute Sant Pau - Universitat Autònoma de Barcelona, Barcelona, Spain
Ladang, Aurélie ; Université de Liège - ULiège > Département de pharmacie > Chimie médicale
Martinez-Yriarte, Jose; Clinical analysis service, Hospital do Meixoeiro, Área Sanitaria de Vigo, Vigo, Spain
Zecca, Chiara; Center for Neurodegenerative Diseases and the Aging Brain, Department of Clinical Research in Neurology, University of Bari "A. Moro" at Pia Fondazione "Cardinale G. Panico", Tricase, Lecce, Italy
Logroscino, Giancarlo; Center for Neurodegenerative Diseases and the Aging Brain, Department of Clinical Research in Neurology, University of Bari "A. Moro" at Pia Fondazione "Cardinale G. Panico", Tricase, Lecce, Italy
Körtvelyessy, Peter; Department of Neurology, Charité Universitätsmedizin Berlin, Berlin, Germany ; Department of Neurology, German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany ; Labor Berlin, Division Innovation, Berlin, Germany
Tumani, Hayrettin; CSF Laboratory, University of Ulm, Ulm, Germany
Parchi, Piero; Department of Biomedical and Neuromotor Sciences (DiBiNeM), University of Bologna, Bologna, Italy ; Department of Clinical Neurobiology, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy
Quadrio, Isabelle; Biochemistry and Molecular Biology Department, Neurodegenerative Pathologies LBMMS Hospices Civils de Lyon, BIORAN Team Lyon Neurosciences Research Center CNRS UMR 5292 INSERM U1028, Lyon, France
Hart, Melanie; Department of Neuroinflammation, UCL Queen Square Institute of Neurology, London, UK
Olsen, Dorte Aalund; Department of Biochemistry and Immunology, University hospital of southern Denmark, Odense, Southern Denmark, Denmark
Alcolea, Daniel; Department of Unitat de Memoria, Hospital de la Santa Creu iSant Pau - Biomedical Research Institute Sant Pau - Universitat Autònoma de Barcelona, Barcelona, Spain ; Department of Neurology, Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas, CIBERNED, Barcelona, Spain
Blennow, Kaj; Department of Clinical Neurochemistry, University of Gothenburg, Mölndal, Gothenburg, Sweden
Fortea, Juan; Department of Unitat de Memoria, Hospital de la Santa Creu iSant Pau - Biomedical Research Institute Sant Pau - Universitat Autònoma de Barcelona, Barcelona, Spain ; Department of Neurology, Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas, CIBERNED, Barcelona, Spain
Lleo, Alberto; Department of Unitat de Memoria, Hospital de la Santa Creu iSant Pau - Biomedical Research Institute Sant Pau - Universitat Autònoma de Barcelona, Barcelona, Spain ; Department of Neurology, Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas, CIBERNED, Barcelona, Spain
Algeciras-Schimnich, Alicia; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA
Ayrignac, Xavier; Department of Neurology, CHU Montpellier, INSERM, Université Montpellier, Montpellier, France
Bedel, Aurélie; Department of Biochimie, CHU de Bordeaux INSERM BRIC U1312 Université de Bordeaux, Bordeaux, France
Santos, Gustavo A A; Department of Surgery and Anatomy, School of Medicine of Ribeirão Preto, University of Sao Paulo, Sao Paulo, Brazil ; Department of Neurology, São Leopoldo MANDIC School of Medicine, Araras, Brazil ; Department of Food and Nutrition, Faculty of Food Engineering, University of Campinas, São Paulo, Brazil
Borelli, Wyllians; Department of Biochemistry, University of Rio Grande do Sul, Porto Alegre, Brazil
Bouaziz-Amar, Elodie; Department of Biochemistry, Hôpital Lariboisière-Fernand Widal APHP, Université Paris Cité Paris, Paris, France
Baldeiras, Inês; Faculty of Medicine of the University of Coimbra and Center for Innovative Biomedicine and Biotechnology, University of Coimbra, Coimbra, Portugal
Bigot-Corbel, Edith; Department of Biochimie, CHU Nantes, Nantes, France
Bjerke, Maria; Vrije Universiteit Brussel Center for Neurosciences, Department of Clinical Biology, Clinical Neurochemistry laboratory, Universitair Ziekenhuis Brussel, Brussels, Belgium
Carretero Perez, Mercedes; Department of Neurology, Santa Cruz de Tenerife, Tenerife, Spain
Casoli, Tiziana; Department of Neurobiology of Ageing, IRCCS INRCA, Ancona, Italy
Chabrashvili, Tinatin; Department of Neurology, SUNY Upstate Medical University, Syracuse, New York, USA
Chapman, Miles D; Neuroimmunology and CSF laboratory, National Hospital for Neurology and Neurosurgery, Queen Square, London, UK
Cusato, Jessica; Department of Medical Sciences, UNITO, Turin, Italy
Dursun, Erdinc; Department of Neuroscience, Institute of Neurological Sciences, Istanbul University-Cerrahpasa, Istanbul, Turkey
Fourier, Anthony; Biochemistry and Molecular Biology Department, Neurodegenerative Pathologies LBMMS Hospices Civils de Lyon, BIORAN Team Lyon Neurosciences Research Center CNRS UMR 5292 INSERM U1028, Lyon, France
Galimberti, Daniela; Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy ; IRCCS, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy
Gezen-Ak, Duygu; Department of Neuroscience, Institute of Neurological Sciences, Istanbul University-Cerrahpasa, Istanbul, Turkey
Gordon, Brian A; Department of Radiology, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA
de Las Heras Florez, Silvia; Department of Neurology, Hospital Universitario Nuestra Señora de Candelaria Santa Cruz de Tenerife, Santa Cruz, Spain
Hernandez Sanchez, Juanjo; Department of Neurology, Unitat de Neuroquímica, Laboratori de Referència de Catalunya, Barcelona, Spain
Herwerth, Marina; Neurology Department, University Hospital Zurich, Zurich, Switzerland
Imperiale, Daniele; Department of Medical Sciences, UNITO, Turin, Italy
Kaczorowski, Flora; Biochemistry and Molecular Biology Department, Neurodegenerative Pathologies LBMMS Hospices Civils de Lyon, BIORAN Team Lyon Neurosciences Research Center CNRS UMR 5292 INSERM U1028, Lyon, France
Kasuga, Kensaku; Department of Molecular Genetics, Brain Research Institute, Niigata University, Niigata, Japan
Keshavan, Ashvini; Dementia Research Centre, UCL Queen Square Institute of Neurology, London, UK
Khalil, Michael; Department of Neurology, Medical University of Graz, Graz, Austria
Kuhle, Jens; Department of Neurology, University Hospital Basel, Basel, Switzerland
Leithner, Christoph; Department of Neurology, Charité Universitätsmedizin Berlin, Berlin, Germany
Lewczuk, Piotr; Department of Psychiatry and Psychotherapy, Universitätsklinikum Erlagen, Erlangen, Germany ; Department of Neurodegeneration Diagnostics, Medical University of Białystok, Białystok, Poland
Tsolaki, Magda; Department of Neurology, AHEPA University Hospital, Thessaloniki, Greece
Giuffrè, Guido Maria; Department of Neuroscience, Catholic University of the Sacred Heart, Rome, Italy
Blanc, Marie-Céline; Biochemistry Department, Cochin hospital, APHP, Paris, France
Mroczko, Barbara; Department of Neurology, Medical University of Bialystok, Bialystok, Poland
Martínez Rodríguez, Jose Enrique; Servei de Neurologia, Neuroimmunology group Hospital del Mar, IMIM, Barcelona, Spain
Musso, Giulia; Department of Medicine, University of Padova, Padova, Italy
Kulczynska-Przybik, Agnieszka; Department of Neurology, Medical University of Bialystok, Bialystok, Poland
Nogueira, Léonor; UMR 5165 CNRS, CHU-PURPAN, Toulouse, France
Paquet, Claire; Department of Neurologie Cognitive, Université de Paris Cité, Paris, France
Baiardi, Simone; Department of Biomedical and Neuromotor Sciences (DiBiNeM), University of Bologna, Bologna, Italy ; Department of Clinical Neurobiology, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy
Gaetani, Lorenzo; Department of Neurology, University of Perugia, Perugia, Italy
Parnetti, Lucilla; Department of Neurology, University of Perugia, Perugia, Italy
Perez Garay, Raquel; Department of Clinical Analysis Service, Cruces University Hospital-OSAKIDETZA, Immunopathology Research Group, Biobizkaia Health Research Institute, Barakaldo, Spain
Poesen, Koen; Alzheimer Research Centre, Leuven Brain Institute, KU Leuven, Leuven, Belgium
Quillard-Muraine, Muriel; Clinical Biology Center, Rouen University Hospital, Rouen, France
Rodriguez Borja, Enrique; Hospital Clinico Universitario de Valencia Laboratorio de Bioquimica Clínica y Patología Molecular, Valencia, Spain
Schraen, Susanna; Department of Biochemistry, CHU de Lille, Lille, France
Terracciano, Daniela; Department of Translational Medical Sciences, University Federico II, Naples, Italy
Bachhuber, Franziska; Department of Translational Medical Sciences, University Federico II, Naples, Italy
Halbgebauer, Steffen; CSF Laboratory, University of Ulm, Ulm, Germany
This manuscript was facilitated by the Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART), through the\u00A0Biofluid-Based Biomarkers PIA\u00A0(Professional Interest Area). The views and opinions expressed by authors in this publication represent those of the authors and do not necessarily reflect those of the PIA membership, ISTAART, or the Alzheimer's Association. The authors thank the French Society of Clinical Biology, the ISTAART BBB-PIA (Biofluid Based Biomarkers PIA [Professional Interest Area] of the Alzheimer's Association), and the Society for Neurochemistry and Clinical CSF analysis for their help in initiating this work.
Yuan A, Rao MV, Veeranna, Nixon RA. Neurofilaments and neurofilament proteins in health and disease. Cold Spring Harb Perspect Biol. 2017;9:a018309. doi:10.1101/cshperspect.a018309
Bocquet A, Berges R, Frank R, Robert P, Peterson AC, Eyer J. Neurofilaments bind tubulin and modulate its polymerization. J Neurosci. 2009;29:11043-11054. doi:10.1523/JNEUROSCI.1924-09.2009
Vineethakumari C, Lüders J. Microtubule anchoring: attaching dynamic polymers to cellular structures. Front Cell Dev Biol. 2022;10:867870. doi:10.3389/fcell.2022.867870
Khalil M, Teunissen CE, Otto M, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14:577-589. doi:10.1038/s41582-018-0058-z
Khalil M, Teunissen CE, Lehmann S, et al. Neurofilaments as biomarkers in neurological disorders—towards clinical application. Nat Rev Neurol. 2024;20:269-287. doi:10.1038/s41582-024-00955-x
Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H. Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry. 2019;90:870-881. doi:10.1136/jnnp-2018-320106
Delaby C, Alcolea D, Carmona-Iragui M, et al. Differential levels of neurofilament light protein in cerebrospinal fluid in patients with a wide range of neurodegenerative disorders. Sci Rep. 2020;10(1):9161. https://doi.org/10.1038/s41598-020-66090-x
Olsson B, Portelius E, Cullen NC, et al. Association of cerebrospinal fluid neurofilament light protein levels with cognition in patients with dementia, motor neuron disease, and movement disorders. JAMA Neurol. 2019;76(3):318-325. doi:10.1001/jamaneurol.2018.3746
Bridel C, van Wieringen WN, Zetterberg H, et al. Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis. JAMA Neurol. 2019;76:1035. doi:10.1001/jamaneurol.2019.1534
Brousse M, Delaby C, Cruz EDL, et al. Serum neurofilament light chain cut-off definition for clinical diagnosis and prognosis of amyotrophic lateral sclerosis. Eur J Neurol. 2023;30(7):1919-1927. doi:10.1111/ene.15813
Ashrafzadeh-Kian S, Figdore D, Larson B, et al. Head-to-head comparison of four plasma neurofilament light chain (NfL) immunoassays. Clin Chim Acta. 2024;561:119817. doi:10.1016/j.cca.2024.119817
Mondésert E, Schraen-Maschke S, Quadrio I, et al. A French multicenter analytical evaluation of the automated Lumipulse G sNfL blood assay (Fujirebio®) and its comparison to four other immunoassays for serum neurofilament light chain assessment in clinical settings. Clin Chim Acta. 2025;565:120007. doi:10.1016/j.cca.2024.120007
Mondesert E, Delaby C, De La Cruz E, et al. Comparative performances of 4 serum NfL assays, pTau181, and GFAP in patients with amyotrophic lateral sclerosis. Neurology. 2025;104:e213400. doi:10.1212/WNL.0000000000213400
Bornhorst JA, Figdore D, Campbell MR, et al. Plasma neurofilament light chain (NfL) reference interval determination in an age-stratified cognitively unimpaired cohort. Clin Chim Acta. 2022;535:153-156. doi:10.1016/j.cca.2022.08.017
Manouchehrinia A, Piehl F, Hillert J, et al. Confounding effect of blood volume and body mass index on blood neurofilament light chain levels. Ann Clin Transl Neurol. 2020;7:139-143. doi:10.1002/acn3.50972
Benkert P, Meier S, Schaedelin S, et al. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Lancet Neurol. 2022;21:246-257. doi:10.1016/S1474-4422(22)00009-6
Abdelhak A, Petermeier F, Benkert P, et al. Serum neurofilament light chain reference database for individual application in paediatric care: a retrospective modelling and validation study. Lancet Neurol. 2023;22:826-833. doi:10.1016/S1474-4422(23)00210-7
Ladang A, Kovacs S, Lengelé L, et al. Neurofilament light chain concentration in an aging population. Aging Clin Exp Res. 2022;34:331-339. doi:10.1007/s40520-021-02054-z
Verberk IMW, Misdorp EO, Koelewijn J, et al. Characterization of pre-analytical sample handling effects on a panel of Alzheimer's disease-related blood-based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group. Alzheimers Dement. 2022;18:1484-1497. doi:10.1002/alz.12510
Coppens S, Lehmann S, Hopley C, Hirtz C. Neurofilament-light, a promising biomarker: analytical, metrological and clinical challenges. Int J Mol Sci. 2023;24:11624. doi:10.3390/ijms241411624
Tang R, Panizzon MS, Elman JA, et al. Association of neurofilament light chain with renal function: mechanisms and clinical implications. Alzheimers Res Ther. 2022;14:189. doi:10.1186/s13195-022-01134-0
Lehmann S, Schraen-Maschke S, Vidal J-S, et al. Blood neurofilament levels predict cognitive decline across the Alzheimer's disease continuum. Int J Mol Sci. 2023;24:17361. doi:10.3390/ijms242417361
Delaby C, Teunissen CE, Blennow K, et al. Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: an international overview. Alzheimers Dement. 2022;18:1868-1879. doi:10.1002/alz.12545
Arslan B, Zetterberg H. Neurofilament light chain as neuronal injury marker—what is needed to facilitate implementation in clinical laboratory practice? Clin Chem Lab Med. 2023;61:1140-1149. doi:10.1515/cclm-2023-0036
Simrén J, Andreasson U, Gobom J, et al. Establishment of reference values for plasma neurofilament light based on healthy individuals aged 5-90 years. Brain Commun. 2022;4:fcac174. doi:10.1093/braincomms/fcac174
Vermunt L, Otte M, Verberk IMW, et al. Age- and disease-specific reference values for neurofilament light presented in an online interactive support interface. Ann Clin Transl Neurol. 2022;9:1832-1837. doi:10.1002/acn3.51676
Fraser CG. Biological variation: a still maturing aspect of laboratory medicine. Adv Lab Med. 2020;1:20190032. doi:10.1515/almed-2019-0032
Jack CR, Andrews JS, Beach TG, et al. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. Alzheimers Dement. 2024;20:5143-5169. doi:10.1002/alz.13859
Ashton NJ, Janelidze S, Al Khleifat A, et al. A multicentre validation study of the diagnostic value of plasma neurofilament light. Nat Commun. 2021;12:3400. doi:10.1038/s41467-021-23620-z
Al Shweiki MR, Steinacker P, Oeckl P, et al. Neurofilament light chain as a blood biomarker to differentiate psychiatric disorders from behavioural variant frontotemporal dementia. J Psychiatr Res. 2019;113:137-140. doi:10.1016/j.jpsychires.2019.03.019
Ducharme S, Dols A, Laforce R, et al. Recommendations to distinguish behavioural variant frontotemporal dementia from psychiatric disorders. Brain. 2020;143:1632-1650. doi:10.1093/brain/awaa018
Scherling CS, Hall T, Berisha F, et al. Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. Ann Neurol. 2014;75:116-126. doi:10.1002/ana.24052
Zetterberg H, Teunissen C, van Swieten J, et al. The role of neurofilament light in genetic frontotemporal lobar degeneration. Brain Commun. 2023;5:fcac310. doi:10.1093/braincomms/fcac310
ClinicalTrials.gov ID NCT04374136. Sponsor Alector Inc. Information provided by Alector Inc. (Responsible Party) Last Update Posted 2025-01-24. ClinicalTrials.gov ID NCT04374136 Sponsor Alector Inc. Information provided by Alector Inc. (Responsible Party) Last Update Posted 2025-01-24
Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134:2456-2477. doi:10.1093/brain/awr179
Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76:1006-1014. doi:10.1212/WNL.0b013e31821103e6
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association; 2013.
Katisko K, Cajanus A, Jääskeläinen O, et al. Serum neurofilament light chain is a discriminative biomarker between frontotemporal lobar degeneration and primary psychiatric disorders. J Neurol. 2020;267:162-167. doi:10.1007/s00415-019-09567-8
Light V, Jones SL, Rahme E, et al. Clinical accuracy of serum neurofilament light to differentiate frontotemporal dementia from primary psychiatric disorders is age-dependent. Am J Geriatr Psychiatry. 2024;32:988-1001. doi:10.1016/j.jagp.2024.03.008
Thouvenot E, Demattei C, Lehmann S, et al. Serum neurofilament light chain at time of diagnosis is an independent prognostic factor of survival in amyotrophic lateral sclerosis. Eur J Neurol. 2020;27:251-257. doi:10.1111/ene.14063
Vacchiano V, Mastrangelo A, Zenesini C, et al. Plasma and CSF neurofilament light chain in amyotrophic lateral sclerosis: a cross-sectional and longitudinal study. Front Aging Neurosci. 2021;13:753242. doi:10.3389/fnagi.2021.753242
Meyer T, Schumann P, Weydt P, et al. Neurofilament light-chain response during therapy with antisense oligonucleotide tofersen in SOD1-related ALS: treatment experience in clinical practice. Muscle Nerve. 2023;67:515-521. doi:10.1002/mus.27818
Giannini LAA, Seelaar H, van der Ende EL, et al. Clinical value of longitudinal serum neurofilament light chain in prodromal genetic frontotemporal dementia. Neurology. 2023;101:e1069-e1082. doi:10.1212/WNL.0000000000207581
Ferullo L, Risi B, Caria F, et al. Gold coast criteria in ALS diagnosis: a real-world experience. Brain Sci. 2024;14:1055. doi:10.3390/brainsci14111055
Verde F, Steinacker P, Weishaupt JH, et al. Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2019;90:157-164. doi:10.1136/jnnp-2018-318704
Novakova L, Zetterberg H, Sundström P, et al. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. Neurology. 2017;89:2230-2237. doi:10.1212/WNL.0000000000004683
Freedman MS, Gnanapavan S, Booth RA, et al. Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management. EBioMedicine. 2024;101:104970. doi:10.1016/j.ebiom.2024.104970
Freedman M, Gnanapavan S. Letter to the editor: consensus statement on neurofilament proteins in multiple sclerosis under development by Consortium Of Multiple Sclerosis Centers (CMSC) expert panel. Int J MS Care. 2020;22:294. doi:10.7224/1537-2073.2020-140
Watanabe M, Nakamura Y, Michalak Z, et al. Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD. Neurology. 2019;93:e1299-e1311. doi:10.1212/WNL.0000000000008160
Horellou P, Flet-Berliac L, Leroy C, et al. Early blood neurofilament light chain and myelin oligodendrocyte glycoprotein antibody levels associate with different disease courses of myelin oligodendrocyte glycoprotein-associated disease in children. Brain Commun. 2023;5:fcad063. doi:10.1093/braincomms/fcad063
Hofmann A, Häsler LM, Lambert M, et al. Comparative neurofilament light chain trajectories in CSF and plasma in autosomal dominant Alzheimer's disease. Nat Commun. 2024;15:9982. doi:10.1038/s41467-024-52937-8
Byrne LM, Schultz JL, Rodrigues FB, et al. Neurofilament light protein as a potential blood biomarker for Huntington's disease in children. Mov Disord. 2022;37(7):1526-1531. doi:10.1002/mds.29027
Steinacker P, Blennow K, Halbgebauer S, et al. Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt-Jakob disease. Sci Rep. 2016;6:38737. doi:10.1038/srep38737
Nitz E, Smitka M, Schallner J, et al. Serum neurofilament light chain in pediatric spinal muscular atrophy patients and healthy children. Ann Clin Transl Neurol. 2021;8:2013-2024. doi:10.1002/acn3.51449
Kessler C, Serna-Higuita LM, Rattay TW, et al. Neurofilament light chain is a cerebrospinal fluid biomarker in hereditary spastic paraplegia. Ann Clin Transl Neurol. 2021;8:1122-1131. doi:10.1002/acn3.51358
Fortea J, Vilaplana E, Carmona-Iragui M, et al. Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. Lancet. 2020;395:1988-1997. doi:10.1016/S0140-6736(20)30689-9
Su C, Zhao K, Xia H, Xu Y. Peripheral inflammatory biomarkers in Alzheimer's disease and mild cognitive impairment: a systematic review and meta-analysis. Psychogeriatrics. 2019;19:300-309. doi:10.1111/psyg.12403
Katzdobler S, Nübling G, Klietz M, et al. GFAP and NfL as fluid biomarkers for clinical disease severity and disease progression in multiple system atrophy (MSA). J Neurol. 2024;271:6991-6999. doi:10.1007/s00415-024-12647-z
Palleis C, Franzmeier N, Weidinger E, et al. Association of neurofilament light chain, [18F]PI-2620 Tau-PET, TSPO-PET, and clinical progression in patients with β-amyloid-negative CBS. Neurology. 2024;102:e207901. doi:10.1212/WNL.0000000000207901
Mollenhauer B, Dakna M, Kruse N, et al. Validation of serum neurofilament light chain as a biomarker of Parkinson's disease progression. Mov Disord. 2020;35:1999-2008. doi:10.1002/mds.28206
Frank A, Bendig J, Schnalke N, et al. Serum neurofilament indicates accelerated neurodegeneration and predicts mortality in late-stage Parkinson's disease. NPJ Parkinsons Dis. 2024;10:14. doi:10.1038/s41531-023-00605-x
McFarland NR. Diagnostic approach to atypical parkinsonian syndromes. Continuum (N Y). 2016;22:1117-1142. doi:10.1212/CON.0000000000000348
Diekämper E, Brix B, Stöcker W, et al. Neurofilament levels are reflecting the loss of presynaptic dopamine receptors in movement disorders. Front Neurosci. 2021;15:690013. doi:10.3389/fnins.2021.690013
Quadalti C, Calandra-Buonaura G, Baiardi S, et al. Neurofilament light chain and α-synuclein RT-QuIC as differential diagnostic biomarkers in parkinsonisms and related syndromes. NPJ Parkinsons Dis. 2021;7:93. doi:10.1038/s41531-021-00232-4
Baiardi S, Rossi M, Giulia Giannini G, et al. Head-to-head comparison of four cerebrospinal fluid and three plasma neurofilament light chain assays in Parkinsonism. NPJ Parkinsons Dis. 2025;11(1):98. doi:10.1038/s41531-025-00951-y
Rajajee V, Muehlschlegel S, Wartenberg KE, et al. Guidelines for neuroprognostication in comatose adult survivors of cardiac arrest. Neurocrit Care. 2023;38:533-563. doi:10.1007/s12028-023-01688-3
Nolan JP, Sandroni C, Böttiger BW, et al. European Resuscitation Council and European Society of Intensive Care Medicine guidelines 2021: post-resuscitation care. Intensive Care Med. 2021;47:369-421. doi:10.1007/s00134-021-06368-4
Panchal AR, Bartos JA, Cabañas JG, et al. Part 3: adult basic and advanced life support: 2020 American Heart Association Guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2020;142:S366-S468. doi:10.1161/CIR.0000000000000916
Rana OR, Schröder JW, Baukloh JK, et al. Neurofilament light chain as an early and sensitive predictor of long-term neurological outcome in patients after cardiac arrest. Int J Cardiol. 2013;168:1322-1327. doi:10.1016/j.ijcard.2012.12.016
Moseby-Knappe M, Mattsson-Carlgren N, Stammet P, et al. Serum markers of brain injury can predict good neurological outcome after out-of-hospital cardiac arrest. Intensive Care Med. 2021;47:984-994. doi:10.1007/s00134-021-06481-4
Wihersaari L, Ashton NJ, Reinikainen M, et al. Neurofilament light as an outcome predictor after cardiac arrest: a post hoc analysis of the COMACARE trial. Intensive Care Med. 2021;47:39-48. doi:10.1007/s00134-020-06218-9
Wihersaari L, Reinikainen M, Furlan R, et al. Neurofilament light compared to neuron-specific enolase as a predictor of unfavourable outcome after out-of-hospital cardiac arrest. Resuscitation. 2022;174:1-8. doi:10.1016/j.resuscitation.2022.02.024
Song H, Bang HJ, You Y, et al. Novel serum biomarkers for predicting neurological outcomes in postcardiac arrest patients treated with targeted temperature management. Crit Care. 2023;27:113. doi:10.1186/s13054-023-04400-1
Levin H, Lybeck A, Frigyesi A, et al. Plasma neurofilament light is a predictor of neurological outcome 12 h after cardiac arrest. Crit Care. 2023;27:74. doi:10.1186/s13054-023-04355-3
Klitholm M, Jeppesen AN, Christensen S, et al. Neurofilament light chain and glial fibrillary acidic protein as early prognostic biomarkers after out-of-hospital cardiac arrest. Resuscitation. 2023;193:109983. doi:10.1016/j.resuscitation.2023.109983
van Tilburg SJ, Teunissen CE, Maas CCHM, et al. Dynamics and prognostic value of serum neurofilament light chain in Guillain-Barré syndrome. EBioMedicine. 2024;102:105072. doi:10.1016/j.ebiom.2024.105072
Altmann P, De Simoni D, Kaider A, et al. Increased serum neurofilament light chain concentration indicates poor outcome in Guillain-Barré syndrome. J Neuroinflammation. 2020;17:86. doi:10.1186/s12974-020-01737-0
Körtvelyessy P, Kuhle J, Düzel E, et al. Ratio and index of neurofilament light chain indicate its origin in Guillain-Barré Syndrome. Ann Clin Transl Neurol. 2020;7:2213-2220. doi:10.1002/acn3.51207
Andersen NE, Boehmerle W, Huehnchen P, Stage TB. Neurofilament light chain as a biomarker of chemotherapy-induced peripheral neuropathy. Trends Pharmacol Sci. 2024;45:872-879. doi:10.1016/j.tips.2024.08.001
Velasco R, Marco C, Domingo-Domenech E, et al. Plasma neurofilament light chain levels in chemotherapy-induced peripheral neurotoxicity according to type of anticancer drug. Eur J Neurol. 2024;31:e16369. doi:10.1111/ene.16369
Kim S-H, Gwak H-S, Lee Y, et al. Evaluation of serum neurofilament light chain and glial fibrillary acidic protein as screening and monitoring biomarkers for brain metastases. Cancers. 2021;13:2227. doi:10.3390/cancers13092227
Ticau S, Sridharan GV, Tsour S, et al. Neurofilament light chain as a biomarker of hereditary transthyretin-mediated amyloidosis. Neurology. 2021;96:e412-e422. doi:10.1212/WNL.0000000000011090
Berends M, Brunger AF, Bijzet J, et al. Longitudinal analysis of serum neurofilament light chain levels as marker for neuronal damage in hereditary transthyretin amyloidosis. Amyloid. 2024;31:132-141. doi:10.1080/13506129.2024.2327342
Fundaun J, Kolski M, Molina-Álvarez M, Baskozos G, Schmid AB. Types and concentrations of blood-based biomarkers in adults with peripheral neuropathies: a systematic review and meta-analysis. JAMA Netw Open. 2022;5:e2248593. doi:10.1001/jamanetworkopen.2022.48593
Kishida T, Tamaki Y, Fukuda M. G3m(21) typing by ELISA and dot immunobinding with enzyme-labeled monoclonal anti-G3m(21) antibody. Z Rechtsmed. 1988;101:15-20. doi:10.1007/BF00205319
Shahim P, Tegner Y, Marklund N, Blennow K, Zetterberg H. Neurofilament light and tau as blood biomarkers for sports-related concussion. Neurology. 2018;90:e1780-e1788. doi:10.1212/WNL.0000000000005518
Shahim P, Politis A, van der Merwe A, et al. Time course and diagnostic utility of NfL, tau, GFAP, and UCH-L1 in subacute and chronic TBI. Neurology. 2020;95:e623-e636. doi:10.1212/WNL.0000000000009985
Thompson AGB, Luk C, Heslegrave AJ, et al. Neurofilament light chain and tau concentrations are markedly increased in the serum of patients with sporadic Creutzfeldt-Jakob disease, and tau correlates with rate of disease progression. J Neurol Neurosurg Psychiatry. 2018;89:955-961. doi:10.1136/jnnp-2017-317793
Kanata E, Golanska E, Villar-Piqué A, et al. Cerebrospinal fluid neurofilament light in suspected sporadic Creutzfeldt-Jakob disease. J Clin Neurosci. 2019;60:124-127. doi:10.1016/j.jocn.2018.09.031
Thompson AGB, Anastasiadis P, Druyeh R, et al. Evaluation of plasma tau and neurofilament light chain biomarkers in a 12-year clinical cohort of human prion diseases. Mol Psychiatry. 2021;26:5955-5966. doi:10.1038/s41380-021-01045-w
Bentivenga GM, Gonzalez-Ortiz F, Baiardi S, et al. Clinical value of novel blood-based tau biomarkers in Creutzfeldt-Jakob disease. Alzheimers Dement. 2025;21(2):e14422. doi:10.1002/alz.14422
Abu-Rumeileh S, Baiardi S, Ladogana A, et al. Comparison between plasma and cerebrospinal fluid biomarkers for the early diagnosis and association with survival in prion disease. J Neurol Neurosurg Psychiatry. 2020;91:1181-1188. doi:10.1136/jnnp-2020-323826
Fortea J, Carmona-Iragui M, Benejam B, et al. Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. Lancet Neurol. 2018;17:860-869. doi:10.1016/S1474-4422(18)30285-0
Davy V, Dumurgier J, Fayosse A, Paquet C, Cognat E. Neurofilaments as emerging biomarkers of neuroaxonal damage to differentiate behavioral frontotemporal dementia from primary psychiatric disorders: a systematic review. Diagnostics. 2021;11:754. doi:10.3390/diagnostics11050754
Forgrave LM, Ma M, Best JR, DeMarco ML. The diagnostic performance of neurofilament light chain in CSF and blood for Alzheimer's disease, frontotemporal dementia, and amyotrophic lateral sclerosis: A systematic review and meta-analysis. Alzheimers Dementia. 2019;11:730-743. doi:10.1016/j.dadm.2019.08.009
Delaby C, Bousiges O, Bouvier D, et al. Neurofilaments contribution in clinic: state of the art. Front Aging Neurosci. 2022;14:1034684. doi:10.3389/fnagi.2022.1034684
Götze K, Vrillon A, Bouaziz-Amar E, et al. Plasma neurofilament light chain in memory clinic practice: evidence from a real-life study. Neurobiol Dis. 2023;176:105937. doi:10.1016/j.nbd.2022.105937
Götze K, Vrillon A, Dumurgier J, et al. Plasma neurofilament light chain as prognostic marker of cognitive decline in neurodegenerative diseases, a clinical setting study. Alzheimers Res Ther. 2024;16:231. doi:10.1186/s13195-024-01593-7
Lombardi V, Carassiti D, Giovannoni G, Lu C-H, Adiutori R, Malaspina A. The potential of neurofilaments analysis using dry-blood and plasma spots. Sci Rep. 2020;10:97. doi:10.1038/s41598-019-54310-y
Truffi M, Garofalo M, Ricciardi A, et al. Neurofilament-light chain quantification by Simoa and Ella in plasma from patients with dementia: a comparative study. Sci Rep. 2023;13:4041. doi:10.1038/s41598-023-29704-8
Kuhle J, Barro C, Andreasson U, et al. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med. 2016;54:1655-1661. doi:10.1515/cclm-2015-1195
Capo X, Galmes-Panades AM, Navas-Enamorado C, et al. Circulating neurofilament light chain levels increase with age and are associated with worse physical function and body composition in men but not in women. Int J Mol Sci. 2023;24:12751. doi:10.3390/ijms241612751
Behzadi A, Pujol-Calderón F, Tjust AE, et al. Neurofilaments can differentiate ALS subgroups and ALS from common diagnostic mimics. Sci Rep. 2021;11:22128. doi:10.1038/s41598-021-01499-6
Illán-Gala I, Alcolea D, Montal V, et al. CSF sAPPβ, YKL-40, and NfL along the ALS-FTD spectrum. Neurology. 2018;91:e1619-e1628. doi:10.1212/WNL.0000000000006383
Poesen K, Van Damme P. Diagnostic and prognostic performance of neurofilaments in ALS. Front Neurol. 2018;9:1167. doi:10.3389/fneur.2018.01167
Brown A, Salo SK, Savage G. Frontal variant Alzheimer's disease: a systematic narrative synthesis. Cortex. 2023;166:121-153. doi:10.1016/j.cortex.2023.05.007
van Lierop ZY, Wessels MH, Lekranty WM, et al. Impact of serum neurofilament light on clinical decisions in a tertiary multiple sclerosis clinic. Mult Scler. 2024;30:1620-1629. doi:10.1177/13524585241277044
Wang Z, Wang R, Li Y, et al. Plasma neurofilament light chain as a predictive biomarker for post-stroke cognitive impairment: a prospective cohort study. Front Aging Neurosci. 2021;13:631738. doi:10.3389/fnagi.2021.631738
Akamine S, Marutani N, Kanayama D, et al. Renal function is associated with blood neurofilament light chain level in older adults. Sci Rep. 2020;10:20350. doi:10.1038/s41598-020-76990-7
